Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Disease-specific quality of life evaluation and its determinants in Cushing's syndrome: what have we learnt?

Badia X, Valassi E, Roset M, Webb SM.

Pituitary. 2014 Apr;17(2):187-95. doi: 10.1007/s11102-013-0484-2. Review.

2.

Psychometric evaluation of the Cushing's Quality-of-Life questionnaire.

Nelson LM, Forsythe A, McLeod L, Pulgar S, Maldonado M, Coles T, Zhang Y, Webb SM, Badia X.

Patient. 2013;6(2):113-24. doi: 10.1007/s40271-013-0012-5.

PMID:
23575965
3.

Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.

Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M.

Eur J Endocrinol. 2014 Jul;171(1):89-98. doi: 10.1530/EJE-13-1013. Epub 2014 Apr 23.

4.

Tuebingen CD-25 is a sensitive tool to investigate health-related quality of life in Cushing's disease patients in the course of the disease.

Milian M, Honegger J, Teufel P, Wolf A, Psaras T.

Neuroendocrinology. 2013;98(3):188-99. doi: 10.1159/000355622. Epub 2013 Nov 6.

PMID:
24080783
5.

Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire.

Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SW, Glusman JE.

Eur J Endocrinol. 2008 May;158(5):623-30. doi: 10.1530/EJE-07-0762.

6.

The development of the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25). Part I: construction and psychometric properties.

Milian M, Teufel P, Honegger J, Gallwitz B, Schnauder G, Psaras T.

Clin Endocrinol (Oxf). 2012 Jun;76(6):851-60. doi: 10.1111/j.1365-2265.2011.04191.x.

PMID:
21801193
7.

The development of the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25). Part II: normative data from 1784 healthy people.

Milian M, Teufel P, Honegger J, Gallwitz B, Schnauder G, Psaras T.

Clin Endocrinol (Oxf). 2012 Jun;76(6):861-7. doi: 10.1111/j.1365-2265.2011.04280.x. Erratum in: Clin Endocrinol (Oxf). 2013 Dec;79(6):901-3.

PMID:
22066792
8.

Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing's syndrome (ERCUSYN).

Badia X, Roset M, Valassi E, Franz H, Forsythe A, Webb SM.

Qual Life Res. 2013 Dec;22(10):2941-50. doi: 10.1007/s11136-013-0396-7. Epub 2013 Mar 29.

9.

Mapping CushingQoL scores onto SF-6D utility values in patients with Cushing's syndrome.

Roset M, Badia X, Forsythe A, Webb SM.

Patient. 2013;6(2):103-11. doi: 10.1007/s40271-013-0010-7.

10.

Personality characteristics and quality of life in patients treated for Cushing's syndrome.

Sonino N, Bonnini S, Fallo F, Boscaro M, Fava GA.

Clin Endocrinol (Oxf). 2006 Mar;64(3):314-8.

PMID:
16487442
11.

Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN.

Valassi E, Feelders R, Maiter D, Chanson P, Yaneva M, Reincke M, Krsek M, Tóth M, Webb SM, Santos A, Paiva I, Komerdus I, Droste M, Tabarin A, Strasburger CJ, Franz H, Trainer PJ, Newell-Price J, Wass JA, Papakokkinou E, Ragnarsson O; ERCUSYN Study Group.

Clin Endocrinol (Oxf). 2018 Mar 24. doi: 10.1111/cen.13600. [Epub ahead of print]

PMID:
29574994
12.

Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice.

Santos A, Resmini E, Martínez-Momblán MA, Crespo I, Valassi E, Roset M, Badia X, Webb SM.

Eur J Endocrinol. 2012 Sep;167(3):337-42. doi: 10.1530/EJE-12-0325. Epub 2012 Jun 7.

13.

Validation of the Tuebingen CD-25 Inventory as a Measure of Postoperative Health-Related Quality of Life in Patients Treated for Cushing's Disease.

Milian M, Kreitschmann-Andermahr I, Siegel S, Kleist B, Führer-Sakel D, Honegger J, Buchfelder M, Psaras T.

Neuroendocrinology. 2015;102(1-2):60-7. doi: 10.1159/000431022. Epub 2015 May 6.

14.

Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience.

Thompson SK, Hayman AV, Ludlam WH, Deveney CW, Loriaux DL, Sheppard BC.

Ann Surg. 2007 May;245(5):790-4.

15.

Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.

Pedroncelli AM.

Neuroendocrinology. 2010;92 Suppl 1:120-4. doi: 10.1159/000314352. Epub 2010 Sep 10. Review.

16.

Quality of life in Cushing's syndrome.

Santos A, Crespo I, Aulinas A, Resmini E, Valassi E, Webb SM.

Pituitary. 2015 Apr;18(2):195-200. doi: 10.1007/s11102-015-0640-y. Review.

PMID:
25647329
17.

Gender differences in presentation and outcome of patients with Cushing's disease in Han Chinese.

Huan C, Qu Y, Ren Z.

Biomed Mater Eng. 2014;24(6):3439-46. doi: 10.3233/BME-141168.

PMID:
25227055
18.

Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities.

Truong HL, Nellesen D, Ludlam WH, Neary MP.

J Med Econ. 2014 Apr;17(4):288-95. doi: 10.3111/13696998.2013.877470. Epub 2014 Mar 11.

PMID:
24617917
19.

Using subscales when scoring the Cushing's quality of life questionnaire.

Tiemensma J, Depaoli S, Felt JM.

Eur J Endocrinol. 2016 Jan;174(1):33-40. doi: 10.1530/EJE-15-0640. Epub 2015 Oct 2.

20.

A specific nursing educational program in patients with Cushing's syndrome.

Martínez-Momblán MA, Gómez C, Santos A, Porta N, Esteve J, Úbeda I, Halperin I, Campillo B, Guillaumet M, Webb SM, Resmini E.

Endocrine. 2016 Jul;53(1):199-209. doi: 10.1007/s12020-015-0737-0. Epub 2015 Sep 23.

Supplemental Content

Support Center